0000950170-24-024006.txt : 20240301
0000950170-24-024006.hdr.sgml : 20240301
20240301170206
ACCESSION NUMBER: 0000950170-24-024006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MACAN WILLIAM ANDREW
CENTRAL INDEX KEY: 0001758584
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38546
FILM NUMBER: 24711316
MAIL ADDRESS:
STREET 1: 24275 KATY FREEWAY, SUITE 600
CITY: KATY
STATE: TX
ZIP: 77494
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neuronetics, Inc.
CENTRAL INDEX KEY: 0001227636
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3222 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 877-600-7555
MAIL ADDRESS:
STREET 1: 3222 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: NEURONETICS INC
DATE OF NAME CHANGE: 20030416
4
1
ownership.xml
4
X0508
4
2024-02-28
0001227636
Neuronetics, Inc.
STIM
0001758584
MACAN WILLIAM ANDREW
C/O NEURONETICS, INC.
3222 PHOENIXVILLE PIKE
MALVERN
PA
19355
false
true
false
false
EVP, GC, CCO and CS
false
Common Stock
2024-02-28
4
S
false
22377
3.16
D
395359
D
Common Stock
2024-02-29
4
S
false
6026
2.94
D
389333
D
Common Stock
2024-02-29
4
A
false
15000
0
A
404333
D
The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a restricted stock unit ("RSU") award.
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.95 to $3.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents a RSU award that vests in three equal annual installments beginning on February 28, 2025, in each case subject to continuous service of the Reporting Person through such date.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
/s/ W. Andrew Macan
2024-03-01